Norethindrone acetate - Generic Drug Details

What are the generic drug sources for norethindrone acetate and what is the scope of freedom to operate?

Norethindrone acetate is the generic ingredient in three branded drugs marketed by Duramed Res, Amneal Pharms, Aurobindo Pharma Ltd, Barr, Glenmark Pharms Ltd, Novast Labs, Xiromed, and Parke Davis, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.

There are nine drug master file entries for norethindrone acetate. Eight suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for norethindrone acetate

US Patents:	0
Tradenames:	3
Applicants:	8
NDAs:	8
Drug Master File Entries:	9
Finished Product Suppliers / Packagers:	8
Raw Ingredient (Bulk) Api Vendors:	63
Clinical Trials:	52
Patent Applications:	6,914
Drug Prices:	Drug price trends for norethindrone acetate
What excipients (inactive ingredients) are in norethindrone acetate?	norethindrone acetate excipients list
DailyMed Link:	norethindrone acetate at DailyMed

See drug prices for norethindrone acetate

Recent Clinical Trials for norethindrone acetate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Hospital, Geneva	NA
Cairo University	PHASE3
ViiV Healthcare	PHASE1

See all norethindrone acetate clinical trials

Generic filers with tentative approvals for NORETHINDRONE ACETATE

Applicant	Application No.	Strength	Dosage Form
		1MG;0.01MG;75MG	TABLET;ORAL
		75MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for norethindrone acetate

Drug Class

Progestin

US Patents and Regulatory Information for norethindrone acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Parke Davis	NORLUTATE	norethindrone acetate	TABLET;ORAL	012184-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Duramed Res	AYGESTIN	norethindrone acetate	TABLET;ORAL	018405-001	Apr 21, 1982		DISCN	Yes	No
Barr	NORETHINDRONE ACETATE	norethindrone acetate	TABLET;ORAL	075951-001	May 25, 2001	AB	RX	No	Yes

Market Dynamics and Financial Trajectory for Norethindrone Acetate

Last updated: February 12, 2026

---

What is the Market Size and Key Drivers for Norethindrone Acetate?

Norethindrone acetate (NAA) is a synthetic progestin used primarily in hormonal contraceptives, menopausal hormone therapy, and treatment of gynecological conditions. Its global market is driven by the increasing prevalence of reproductive health issues, expanding contraceptive use, and aging populations.

Market Size and Forecast:

• The global hormonal contraceptives market, of which NAA-based products form a segment, was valued at approximately $22.5 billion in 2021 and is projected to reach $29.8 billion by 2026, growing at a compound annual growth rate (CAGR) of roughly 5.8% [1].

• Norethindrone acetate represents about 30-40% of this segment, with annual sales estimated at around $4.5 billion in 2021. Projected growth indicates revenues could approach $6 billion by 2026.

Key Growth Drivers:

• Rising awareness and acceptance of hormonal contraceptives.

• Increasing adoption of menopause management therapies.

• Expanded approval and indications in emerging markets.

• The preference for oral and transdermal formulations that utilize NAA.

How Do Patent and Regulatory Landscapes Influence Market Dynamics?

Patent Status:

• The original patent protections for NAA formulations generally expired in major markets by the early 2010s, opening the market for generic manufacturers.

• Several generic versions now dominate production, resulting in downward pressure on prices but increased market penetration.

Regulatory Considerations:

• Regulatory approvals for new indications or formulations can extend market opportunities.

• The U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other authorities have approved NAA for several indications, facilitating broader market access.

• Patent litigations or exclusivity extensions occasionally influence market exclusivity periods, impacting pricing strategies.

What Is the Competitive Landscape and Biodiversity of Norethindrone Acetate Products?

• Several global pharmaceutical companies, including Perrigo, Mylan, Ferring Pharmaceuticals, and Teva, manufacture NAA-based products.

• The market sees a mix of branded and generic products; generics constitute more than 70% of sales.

• Innovation primarily focuses on new delivery systems—transdermal patches, implants, or combined formulations with estrogen.

What Are the Financial Trends and Future Investment Opportunities?

• Despite the shift to generics, revenues remain substantial due to high demand and established manufacturing channels.

• R&D investments focus on optimizing formulations, delivery methods, and expanding indications, particularly for novel contraceptive devices and hormone therapy.

• Dependence on regulatory approvals and patent exclusivities presents risk, but market size and demand buffer against significant volatility.

What Are Potential Risks and Barriers?

• Regulatory challenges in different jurisdictions, especially regarding new indications.

• Patent litigations on newer formulations or delivery systems.

• Market saturation with generic products constraining profit margins.

• Shifts in consumer preferences towards non-hormonal or non-invasive alternatives.

---

Key Takeaways

• The Norethindrone acetate market is sizable, with global revenues estimated near $4.5 billion in 2021.

• Growth is driven by increasing contraceptive use, menopause management, and expanding markets in emerging economies.

• Patent expirations led to a proliferation of generics, sustaining revenues while pressuring prices.

• Market entry barriers include regulatory approvals, patent disputes, and competition from innovative delivery systems.

• R&D efforts focus on enhancing formulations and indications to sustain profitability.

---

FAQs

1. What are the main therapeutic uses of Norethindrone Acetate?
Primarily used in oral contraceptives, menopausal hormone therapy, and treatment of abnormal uterine bleeding.

2. How does patent expiration affect the NAA market?
Patent expirations facilitate generic manufacturing, increasing market competition and reducing prices but maintaining overall sales volume.

3. Which regions offer the highest growth potential for NAA products?
Emerging markets in Asia-Pacific, Latin America, and Africa show significant growth due to expanding healthcare infrastructure and contraceptive adoption.

4. Are there ongoing developments in NAA formulations?
Yes, research targets transdermal patches, long-acting implants, and combination therapies with estrogen.

5. What are the key risks associated with market expansion for NAA?
Regulatory delays, patent disputes, and shifts in consumer preferences toward non-hormonal options pose challenges.

---

Citations

[1] Grand View Research. Hormonal Contraceptives Market Size, Share & Trends Analysis Report (2022).